Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Toni Widmer

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|May 16, 2015
Transformation of acidic poorly water soluble drugs into ionic liquidsAnja Balk, Johannes Wiest, Toni Widmer, et al.
Pharmaceutical Research|May 26, 2023
Protein Based Amorphous Solid Dispersion: a Case Study Investigating Different Whey Proteins at High Drug LoadingDonglei Leng, Bulut Bulduk, Toni Widmer, et al.
Chemmedchem|May 1, 2010
The binding mode of side chain- and C3-modified epothilones to tubulinMáté Erdélyi, Armando Navarro-Vázquez, Bernhard Pfeiffer, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|January 5, 2018
Utility of food pellets containing 1-aminobenzotriazole for longer term in vivo inhibition of cytochrome P450 in miceRowan Stringer, Valerie Cordier, Catherine Afatsawo, et al.
Pharmaceutical Research|December 24, 2014
Ionic liquid versus prodrug strategy to address formulation challengesAnja Balk, Toni Widmer, Johannes Wiest, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|November 4, 2017
Mapping the pharmaceutical design space by amorphous ionic liquid strategiesJohannes Wiest, Marco Saedtler, Anja Balk, et al.
Journal of Medicinal Chemistry|January 24, 2018
Discovery of the First Potent, Selective, and Orally Bioavailable Signal Peptide Peptidase-Like 2a (SPPL2a) Inhibitor Displaying Pronounced Immunomodulatory Effects In VivoJuraj Velcicky, Ursula Bodendorf, Pascal Rigollier, et al.
Journal of Medicinal Chemistry|May 2, 2022
Identification of NVP-CLR457 as an Orally Bioavailable Non-CNS-Penetrant pan-Class IA Phosphoinositol-3-Kinase InhibitorRobin A Fairhurst, Pascal Furet, Patricia Imbach-Weese, et al.
Cancer Discovery|April 11, 2022
Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12CAndreas Weiss, Edwige Lorthiois, Louise Barys, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|May 16, 2015
Transformation of acidic poorly water soluble drugs into ionic liquidsAnja Balk, Johannes Wiest, Toni Widmer, et al.
Pharmaceutical Research|May 26, 2023
Protein Based Amorphous Solid Dispersion: a Case Study Investigating Different Whey Proteins at High Drug LoadingDonglei Leng, Bulut Bulduk, Toni Widmer, et al.
Chemmedchem|May 1, 2010
The binding mode of side chain- and C3-modified epothilones to tubulinMáté Erdélyi, Armando Navarro-Vázquez, Bernhard Pfeiffer, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|January 5, 2018
Utility of food pellets containing 1-aminobenzotriazole for longer term in vivo inhibition of cytochrome P450 in miceRowan Stringer, Valerie Cordier, Catherine Afatsawo, et al.
Pharmaceutical Research|December 24, 2014
Ionic liquid versus prodrug strategy to address formulation challengesAnja Balk, Toni Widmer, Johannes Wiest, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|November 4, 2017
Mapping the pharmaceutical design space by amorphous ionic liquid strategiesJohannes Wiest, Marco Saedtler, Anja Balk, et al.
Journal of Medicinal Chemistry|January 24, 2018
Discovery of the First Potent, Selective, and Orally Bioavailable Signal Peptide Peptidase-Like 2a (SPPL2a) Inhibitor Displaying Pronounced Immunomodulatory Effects In VivoJuraj Velcicky, Ursula Bodendorf, Pascal Rigollier, et al.
Journal of Medicinal Chemistry|May 2, 2022
Identification of NVP-CLR457 as an Orally Bioavailable Non-CNS-Penetrant pan-Class IA Phosphoinositol-3-Kinase InhibitorRobin A Fairhurst, Pascal Furet, Patricia Imbach-Weese, et al.
Cancer Discovery|April 11, 2022
Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12CAndreas Weiss, Edwige Lorthiois, Louise Barys, et al.
Pageof 1